Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 5CNS 5NET 4Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Pituitary Neoplasms 1Pheochromocytoma 1Parathyroid Neoplasms 1Paraganglioma 1Carcinoma, Medullary 1

Interventions

Specimen Handling 2Radiotherapy 2Magnetic Resonance Spectroscopy 2tipifarnib 1pentetreotide 1lutetium Lu 177 dotatate 1gallium Ga 68 dotatate 1fostamatinib 1fluorodopa F 18 1fludarabine phosphate 1cabozantinib 1atezolizumab 1Tamoxifen 1Ritonavir 1Quality of Life 1Patient Reported Outcome Measures 1Octreotide 1Nivolumab 1Molecular Diagnostic Techniques 1Ipilimumab 1Interleukin-13 1Indinavir 1Immunotherapy 1Genetic Testing 1Fluorodeoxyglucose F18 1Drug Therapy 1Doxorubicin 1Cyclophosphamide 1Cryosurgery 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pheochromocytoma × lutetium Lu 177 dotatate × Head & Neck × Clear all
NCT04106843 2020-09-07

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

M.D. Anderson Cancer Center

Phase 2 Withdrawn
CNSEndocrineHead & Neck

Paraganglioma, Parathyroid Neoplasms, Pheochromocytoma, Pituitary Neoplasms, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡